Free Trial

Illumina (ILMN) Stock Forecast & Price Target

$116.11
-1.50 (-1.28%)
(As of 03:42 PM ET)

Illumina - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 21 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 10 have given a hold rating, and 9 have given a buy rating for ILMN.

Consensus Price Target

$158.57
36.57% Upside
High Forecast$242.00
Average Forecast$158.57
Low Forecast$100.00

According to the 21 analysts' twelve-month price targets for Illumina, the average price target is $158.57. The highest price target for ILMN is $242.00, while the lowest price target for ILMN is $100.00. The average price target represents a forecasted upside of 36.57% from the current price of $116.11.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
10 Hold rating(s)
11 Hold rating(s)
9 Hold rating(s)
6 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$158.57$158.14$167.70$249.68
Forecasted Upside36.57% Upside24.30% Upside23.58% Upside18.14% Upside
Get Illumina Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside36.64% Upside3,082.09% Upside9.39% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024Stephens
4 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$170.00 ➝ $170.00+59.36%
7/10/2024Citigroup
3 of 5 stars
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$140.00+31.23%
7/1/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$249.00 ➝ $242.00+124.61%
6/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$195.00 ➝ $175.00+59.35%
6/6/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$140.00 ➝ $122.00+7.96%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
5/6/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$185.00 ➝ $176.00+48.26%
5/3/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$125.00 ➝ $128.00+3.23%
4/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$85.00 ➝ $100.00-23.47%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
1/16/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$155.00+22.37%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
11/13/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$200.00 ➝ $190.00+104.76%
11/10/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$210.00 ➝ $120.00+22.17%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%
8/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$235.00 ➝ $190.00+2.16%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$225.00 ➝ $200.00+8.41%
8/8/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$240.00 ➝ $230.00+25.10%
2/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Souda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$249.00 ➝ $250.00+15.88%
1/25/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$350.00 ➝ $296.00+42.78%
11/7/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$240.00 ➝ $225.00+3.19%
11/4/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$327.00 ➝ $350.00+65.15%
8/15/2022Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$190.00-16.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 04:13 PM ET.

ILMN Forecast - Frequently Asked Questions

What is Illumina's forecast for 2024?

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $158.57, with a high forecast of $242.00 and a low forecast of $100.00.

Should I buy or sell Illumina stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 10 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

Does Illumina's stock price have much upside?

According to analysts, Illumina's stock has a predicted upside of 26.75% based on their 12-month stock forecasts.

Has Illumina been upgraded by Wall Street analysts recently?

Over the previous 90 days, Illumina's stock had 1 upgrade by analysts.

What analysts cover Illumina?

Illumina has been rated by research analysts at Citigroup, Evercore ISI, Jefferies Financial Group, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stephens, and TD Cowen in the past 90 days.

Do Wall Street analysts like Illumina more than its competitors?

Analysts like Illumina less than other "medical" companies. The consensus rating for Illumina is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners